2015 NAS Interindividual Variability Workshop | September 30, 2015 Integrating In Vitro and In Silico Methods to Evaluate Variability Barbara A. Wetmore.

Slides:



Advertisements
Similar presentations
Human risk assessment perspectives for high risk conditions
Advertisements

Perspectives from EPA’s Endocrine Disruptor Screening Program
Dosimetry in Risk Assessment and a bit More Mel Andersen McKim Conference QSAR and Aquatic Toxicology & Risk Assessment June 27-29, 2006.
Advanced Medicinal Chemistry
Office of Research and Development Computational Toxicology and High-Throughput Risk Assessment Richard Judson U.S. EPA, National Center for Computational.
UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014
Improving Candidate Quality Through the Prediction of Clinical Outcome.
Charlie Taylor, PhD CpTaylor Consulting Chelsea, MI, USA
Grapefruit: Inhibits CYP3A4 Edwards, et al. Drug Metab. Disp. 24:1287, dihydroxybergamottin F FP of high-E drugs is significantly elevated when given.
American Conference on Pharmacometics –San Diego, CA; April Population PK modeling incorporating enzyme induction mechanism to guide the design.
Pharmacokinetics as a Tool
The higher BUP-to-NBUP ratio (0.7—19.19) than adults (0.165—1.4) has been observed in newborn patients studied. It might be due to immature hepatic function.
National Institute for Public Health and the Environment 1 Integrated probabilistic risk assessment Bas Bokkers National Institute for Public Health and.
Mechanistic PBPK as an aid in identifying the size of covariate effects and design of POPPK studies: An example focusing on haematocrit as a determinant.
Risk Assessment.
Risk Assessment II Dec 9, Is there a “safe” dose ? For effects other than cancer:
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
CYP2C8 and Drug Interactions
DRUG TREATMENT IN THE ELDERLY. THE BASIC PROBLEM Drug treatment increases (almost exponentially) with age The elderly are presumed to be - because of.
Lynn H. Pottenger, PhD, DABT The Dow Chemical Company
Karel Allegaert, MD PhD UZ Leuven determinants of variability in disposition of exogenous compounds in neonates Clinical research supported by the Fund.
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
Virtual Drug Development in Southern California, A Pre-Clinical Focus in vitro tests to support IND submissions David Johnson, Ph.D. Director, DMPK MicroConstants,
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Approaches for Evaluating the Relevance of Multiroute Exposures in Establishing Guideline Values for Drinking Water Contaminants Kannan Krishnan, Université.
Nonlinear Pharmacokinetics
Animal Studies and Human Health Consequences Sorell L. Schwartz, Ph.D. Department of Pharmacology Georgetown University Medical Center.
Using Spotfire DecisionSite to Realize the Full Value of High-Throughput Screening ADME Data Eric Milgram Pfizer Global Research & Development – La Jolla.
Risk Assessment Nov 7, 2008 Timbrell 3 rd Edn pp Casarett & Doull 7 th Edn Chapter 7 (pp )
 The Hamner Institutes for Health Sciences | June 7, 2011 Integration of Dosimetry, Human Exposure and High-Throughput Screening Data in the Toxicity.
Supplementary Fig. 2. Statistical Classification Analysis Results. Box and whisker plots displaying mean performance metrics returned in the assessment.
Biomarkers Biomarkers - markers in biological systems with a sufficently long half-life which allow location where in the biological system change occur.
EMEA London Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.
Atelier PK sur articles. 5 thèmes Absorption / biodisponibilité Métabolisme hépatique et effet de premier passage Les modèles in vitro d’étude de l’absorption.
Model structure  Law of mass action applied to describe the reversible solifenacin-AGP, solifenacin-albumin and solifenacin-VBC binding  VBC positioned.
VARIABILITY IN PHARMACOKINETICS & PATIENT RESPONSE Dr. Mohd B. Makmor Bakry, Ph.D., RPh Senior Lecturer in Clinical Pharmacy Universiti Kebangsaan Malaysia.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Clinical Pharmacokinetics of Carbamazepine
Chief Scientific Officer, CellzDirect, Inc.
Modeled effects of metabolism on chemical bioaccumulation in fish J. Nichols, P. Fitzsimmons, L. Burkhard U.S. Environmental Protection Agency, Office.
Global and Regional estimates of the Burden Due to Ambient Air Pollution: results from GBD ST AFRICA/MIDDLE-EAST EXPERT MEETING AND WORKSHOP ON THE.
An Overview of the Objectives, Approach, and Components of ComET™ Mr. Paul Price The LifeLine Group All slides and material Copyright protected.
Introduction to Hurel ISSX H µ REL ® C ORPORATION.
Opening Remarks -- Ozone and Particles: Policy and Science Recent Developments & Controversial Issues GERMAN-US WORKSHOP October 9, 2002 G. Foley *US EPA.
Shirley M. Tsunoda Liver Transplant, Drug Metabolism/PK Research Interests Investigating the genetic and environmental factors that influence variability.
Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs) M Shelton, S Ford, M Anderson, S Murray, J Ng-Cashin XVI.
MS Phoenix WinNonLin Project
NUATRC/TCEQ Air Toxics Workshop October Air Toxics Air Toxics: What We Know, What we Don’t Know, and What We Need to Know Human Health Effects –
Simultaneous evaluation of the activity of five cytochrome P450 enzymes by a cocktail study in healthy volunteers Department of Pharmacy Practice & Sciences.
CYP
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Drug Transfer into Milk: Clinical Methods & Issues Patrick J. McNamara University of Kentucky College of Pharmacy College of Pharmacy.
Development of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model to Quantitate Biomarkers of Exposure to Organophosphorus Insecticides.
Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.
Do We Need to Optimize Protein Binding in Drug Discovery? NEDMDG Summary Meeting Xingrong Liu, Ph.D. Genentech.
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
Innovative Research for a Sustainable Future mg kg -1 d -1 * For more information please send to: AbstractOngoing.
Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.
Dynamic energy budgets in individual based population models
In Vitro Metabolism and Prediction of Drug-Drug Interaction of the Calcimimetic Agent Cinacalcet HCl Manoj Bajpai, Joel Esmay, Victor Chi, Mike Hayashi,
Dr. Daniele Wikoff – ToxStrategies Experimental Biology 2017
Risk Assessment Dec 4 -6, 2006.
10 – BIOMARKERS Introduction
Use of Physiologically Based Pharmacokinetic (PBPK) Models to Support Canine Drug Product Development Devendra Pade1, Marilyn Martinez2, Bipin Mistry2.
Decision Contexts in a Changing Toxicology Paradigm
Senior Medical Director, Cardiovascular
Biopharmaceutics Dr Mohammad Issa Saleh.
Case Study: Risk – Risk Comparison n-Propyl Bromide vs
Regulatory Sciences and Government Affairs
Therapeutic Drug Monitoring chapter 1 part 1
Presentation transcript:

2015 NAS Interindividual Variability Workshop | September 30, 2015 Integrating In Vitro and In Silico Methods to Evaluate Variability Barbara A. Wetmore The Hamner Institutes for Health Sciences Research Triangle Park, NC USA

2015 NAS Interindividual Variability Workshop | September 30, 2015 Broad-Based Movement in Toxicology Towards In Vitro Testing and Hazard Prediction

2015 NAS Interindividual Variability Workshop | September 30, 2015 HT Toxicity Testing Data Difficulty Translating Nominal Testing Concentrations into In Vivo Doses Knudsen et al. Toxicology 282:1-15, 2011

2015 NAS Interindividual Variability Workshop | September 30, 2015 Prioritization and Hazard Prediction Based on Nominal Concentrations Can Misrepresent Potential Health Risks Protein Binding Metabolic Clearance Bioavailability van de Waterbeemd and Gifford, Nat Rev Drug Disc 2:192, 2003 Reif et al. Environ Hlth Perspect 118:1714, 2010

2015 NAS Interindividual Variability Workshop | September 30, 2015 Incorporating Dosimetry with High-Throughput Screening Data Human Hepatocytes (10 donor pool) Human Plasma (6 donor pool) Hepatic Clearance Plasma Protein Binding Population-Based In Vitro-to-In Vivo Extrapolation Population-Based In Vitro-to-In Vivo Extrapolation Plasma Concentration at Steady State for 10,000 Healthy Individuals of Both Sexes from 20 to 50 Yrs Old Setting the Stage…

2015 NAS Interindividual Variability Workshop | September 30, 2015 Using Reverse Dosimetry to Estimate Population-Based Oral Equivalent Doses Upper 95 th Percentile Css Among 10,000 Healthy Individuals of Both Sexes from 20 to 50 Yrs Old Plasma Concentration ToxCast AC 50 Value Assay X (e.g., ACE inhibition) Oral Exposure Oral Dose Required to Achieve Steady State Plasma Concentrations Equivalent to AC 50 Oral Equivalent (mg/kg/day) ToxCast AC 50 (uM) 1 mg/kg/day Upper 95 th Percentile Css (uM) = 1 mg/kg/day Oral Exposure Metabolic and binding parameters Setting the Stage…

2015 NAS Interindividual Variability Workshop | September 30, 2015 Incorporating Dosimetry and Exposure with HTS Data

2015 NAS Interindividual Variability Workshop | September 30, 2015 Primary Hepatocytes Hepatic Clearance Cl in vitro Plasma C ss General Population ≠ Plasma C ss General Population Dosimetry and Exposure Strategy Limited to General Population

2015 NAS Interindividual Variability Workshop | September 30, 2015 The Impact of Population Variability on Risk Assessment Clearance results for full database (27 substrates). from Ginsberg et al., 2002, Toxicol. Sci., 66, Ratio to young adults Age (years) from Ginsberg et al., 2005, Environ. Health Persp., 113, Clearance differences span across multiple newborn and juvenile life stages… … as well as geriatric life stages.

2015 NAS Interindividual Variability Workshop | September 30, 2015 Percent contribution of individual CYPs to total hepatic clearance of xanthines. Ginsberg et al., 2004, J. Toxicol. Env. Health Pt. A, 67: The Impact of Population Variability on Risk Assessment Cresteil, 1998, Food Addit. Contam., 15: Ontogeny of Human Hepatic CYP Isozymes Frequency for CYP2D6 alleles classified as functional, non-functional and reduced functioning for various subpopulations. Bradford, 2002, Pharmacogenomics. 3(2): Sole reliance on pharmacokinetic data for a “generic” population could lead to a significant underestimation of risk to a susceptible lifestage or subpopulation

2015 NAS Interindividual Variability Workshop | September 30, 2015 CYP1A2 CYP2D6 CYP2C8 CYP2E1 UGT1A4 CYP3A5 CYP3A4 CYP2C19 UGT1A1 CYP2C9 CYP2B6 UGT2B7 Population-based In Vitro-In Vivo Extrapolation Primary Hepatocytes Hepatic Clearance Cl in vitro Plasma C ss General Population CYP1A2 CYP… CYP3A4 UGT… Cl rCYP1A2 Cl rCYP… Cl rCYP3A4 Cl rUGT… Plasma C ss for: Neonates Northern Europeans Asians Children And so on… Intrinsic Clearance Rates rCYP1A2 rCYP3A4 rCYP… rUGT …

2015 NAS Interindividual Variability Workshop | September 30, 2015 Integrating High-Throughput Pharmacokinetics with the ToxCast In Vitro Assays Reverse Dosimetry Oral Exposure Plasma Concentration ToxCast AC 50 Value Oral Dose Required for Specific Subpopulations to Achieve Steady State Plasma Concentrations Equivalent to In Vitro Bioactivity ~600 In Vitro ToxCast Assays Oral Equivalent Dose (mg/kg/day) What are humans exposed to? ? ? ? Chemical In Vitro Bioactivity Recombinant Enzyme Metabolism Human Plasma Protein Binding Population-Based IVIVE Model Steady State Plasma Concentrations for Different Lifestages or Subpopulations Least Sensitive Assay Most Sensitive Assay Wetmore et al., 2014, Toxicol Sci, 142(1):

2015 NAS Interindividual Variability Workshop | September 30, 2015 No UGT metabolism detected Carbaryl Difenoconazole Recombinant Isozyme Clearance Rates

2015 NAS Interindividual Variability Workshop | September 30, 2015 Incorporating Recombinant Phase I and II Enzyme Data into IVIVE Modeling Cl int = intrinsic clearance ISEF = Cl int, HLM Cl int, rCYP x HLM CYP abundance HLM = human liver microsomes rCYP = recombinant CYP isoform (pmol P450 / mg protn) (dimensionless) (uL / min / mg protn) (uL / min*pmol P450) Hepatic CYP Isozyme Abundance in Healthy Adults (% of Total) Scaling rCYP Data to HLM using intersystem extrapolation factors

2015 NAS Interindividual Variability Workshop | September 30, 2015 Combining Isozyme Clearance and Abundance Data to Determine Fraction Metabolized IsozymeNo. Chemicals % fm > 5% % fm RangeChemicals with % fm > 5% CYP1A Bensulide, Carbaryl, Fludioxonil CYP2C Azoxystrobin, Bensulide, Carbaryl, Difenoconazole, Haloperidol, Tebupirimfos CYP3A Acetochlor, Azoxystrobin, Bensulide, Difenoconazole, Haloperidol, Lovastatin Tebupirimfos CYP3A Lovastatin, Tebupirimfos UGT1A Haloperidol, Tebupirimfos UGT1A Difenoconazole, Haloperidol, Lovastatin

2015 NAS Interindividual Variability Workshop | September 30, 2015 Comparison of C ss Values Derived Across Multiple Lifestages and Subpopulations Upper 95 th percentile C ss Lifestage or Subpopulation (Age (yr) or Ethnic) Lifestage or Subpopulation (Age (yr) or Ethnic) Healthy Chinese Japanese North European Diabetic Renal Insufficiency Healthy Chinese Japanese North European Diabetic Renal Insufficiency HK AF =11.4 HK AF =11.5

2015 NAS Interindividual Variability Workshop | September 30, 2015 Comparison of C ss Values Derived Across Multiple Lifestages and Subpopulations Lifestage or Subpopulation (Age (yr) or Ethnic) Lifestage or Subpopulation (Age (yr) or Ethnic) Healthy Chinese Japanese North European Diabetic Renal Insufficiency Healthy Chinese Japanese North European Diabetic Renal Insufficiency HK AF =3.5 HK AF =6.7

2015 NAS Interindividual Variability Workshop | September 30, 2015 Wetmore et al., 2014, Toxicol Sci. 142(1): Comparison of C ss Values Derived Across Multiple Lifestages and Subpopulations

2015 NAS Interindividual Variability Workshop | September 30, 2015 Agreement between In Vivo and IVIVE-derived C ss Values using Recombinant CYP-based Clearance Rates Chemical In vivo PK C ss (  M) IVIVE C ss (  M) Carbaryl Haloperidol Lovastatin

2015 NAS Interindividual Variability Workshop | September 30, 2015 Estimated Chemical-Specific Toxicokinetic Adjustment Factors ChemicalMedian C ss for Healthy Population 95 th Percentile C ss for Most Sensitive Most Sensitive Estimated HK AF % Contribution of Isozyme Differences to Average HK AF Acetochlor Neonatal6.786 Azoxystrobin Neonatal6.786 Bensulide Neonatal4.079 Carbaryl Neonatal Difenoconazole Renal Insufficiency Fludioxonil Neonatal Haloperidol Neonatal4.983 Lovastatin Neonatal6.590 Tebupirimfos Renal Insufficiency 3.515

2015 NAS Interindividual Variability Workshop | September 30, 2015 ♦ ● ▼ ■ ▲ ■ ▲ ♦ Matching Oral Equivalent Doses and Exposure Estimates for Different Populations ● ▼ ♠ ♠ Subpopulation or Lifestage (Age (yr) or Ethnic) Subpopulation or Lifestage (Age (yr) or Ethnic)

2015 NAS Interindividual Variability Workshop | September 30, 2015 Matching Oral Equivalent Doses and Exposure Estimates for Different Populations

2015 NAS Interindividual Variability Workshop | September 30, 2015 Incorporating Population TD Variability with PK Variability Abdo et al. 2015, Environ Int Sep 17; 85:

2015 NAS Interindividual Variability Workshop | September 30, 2015 Key Points First comprehensive attempt to combine physiologic and PK differences to quantitate variability anticipated between life stage-, ethnic- and disease- based populations. First effort to evaluate PK variability in a manner that could 1) identify sensitive populations and 2) replace use of default safety factors in risk assessment. Subpopulation- or lifestage- based pharmacodynamic differences will also contribute to the variable susceptibilities that may be observed following chemical exposure. Tools are emerging that allow the incorporation of pharmacokinetic with pharmacodynamic variability.

2015 NAS Interindividual Variability Workshop | September 30, 2015 Acknowledgements Hamner - Institute for Chemical Safety Sciences Rusty Thomas (EPA-NCCT) John Wambaugh (EPA-NCCT) Lisa M. Almond (Simcyp) Masoud Jamei (Simcyp) External Collaborators American Chemistry Council – Long Range Initiative Funding Brittany Allen Mel Andersen Harvey Clewell Alina Efremenko Eric Healy Timothy Parker Reetu Singh Mark Sochaski Longlong Yang